Longevity & AgingNew Amylin Drug Petrelintide Delivers 10% Weight Loss With Half the GI Side Effects of GLP-1s
A new investigational weight-loss drug called petrelintide showed promising results in a global phase II trial. The weekly self-injected drug, an amylin analog, helped people with obesity or overweight lose roughly 9–11% of their body weight over 42 weeks when combined with diet and exercise. Crucially, it caused significantly fewer gastrointestinal side effects than GLP-1 drugs like semaglutide — roughly half the rates of nausea and vomiting. Researchers suggest it could become a first-line obesity treatment in primary care settings, particularly for patients who don't need the cardiovascular or liver-specific benefits that GLP-1s offer. The drug works through a different brain pathway than GLP-1s, raising the possibility of combining both drug classes for additive effects.
